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ABSTRACT 
Purpose: To evaluate toxicity and efficacy of chemoradiotherapy with temozolomide 
(TMZ) administered in an intensified one week on/one week off schedule plus 
indomethacin (INDO) in patients with newly diagnosed glioblastoma. 
Patients and Methods: Forty-one adult patients (median Karnofsky performance 
status 90%; median age, 56 years) were treated with pre-irradiation TMZ at 150 
mg/m2 (one week on/one week off), involved-field radiotherapy combined with 
concomitant low-dose TMZ (50 mg/m2), maintenance TMZ starting at 150 mg/m2 
according to a one week on/one week off schedule, plus maintenance INDO (25 mg 
bid) treatment. 
Results: The median follow-up interval was 21.7 months. Grade 4 hematotoxicity 
was observed in 15 patients (36.6%). Treatment-related non-hematologic grade 4-5 
toxicities were reported for two patients (4.9%). The median progression-free 
survival (PFS) was 7.6 months [95% CI, 6.2 to 10.4 months]. The one year survival 
rate was 73.2% [95% CI, 56.8 to 84.2%]. O6-Methylguanine-DNA methyltransferase 
(MGMT) gene promoter methylation in the tumor tissue was associated with 
significantly superior PFS. 
Conclusions: The dose-dense regimen of TMZ administered in a one week on/one 
week off schedule resulted in acceptable non-hematologic toxicity. Compared to data 
from the EORTC/NCIC trial 26981-22981/CE.3, patients with an unmethylated 
MGMT gene promoter appeared not to benefit from intensifying the TMZ schedule 
regarding median PFS and overall survival, whereas data are promising for patients 
with methylated MGMT promoter. 
Key words: Glioblastoma, Indomethacin, O6-methylguanine-DNA methyltransferase 
(MGMT), Radiotherapy, Temozolomide. 
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INTRODUCTION 
The current standard of care in the treatment of newly diagnosed glioblastoma is 
combined chemoradiotherapy with concomitant and adjuvant temozolomide (TMZ) 
according to the phase III trial jointly conducted by the European Organisation for 
Research and Treatment of Cancer (EORTC) and the National Cancer Institute of 
Canada (NCIC) (1). This trial also demonstrated that hypermethylation of the 
promoter region of the DNA repair gene O6-methylguanine-DNA methyltransferase 
(MGMT) which partially mediates chemoresistance against alkylating agents such as 
TMZ or the nitrosoureas (2) correlates with improved survival in patients treated with 
combined radiotherapy and TMZ (3). TMZ dosing schedules allowing a more 
prolonged exposure may result in higher cumulative doses (4–6) than the standard 
5-day regimen (7) and may deplete MGMT in the tumor, thus sensitizing tumor cells 
to the toxic effects of TMZ. However, depletion of MGMT by prolonged exposure to 
TMZ not only affects tumor cells but also normal cells, particularly hematopoietic 
precursor cells, potentially enhancing hematologic toxicity (5). Other dose-dense 
TMZ regimens did not show an unusual incidence of toxicities and also 
demonstrated promising efficacy data at recurrence (6). 
Preclinical and clinical studies suggest anti-tumoral effects of cyclooxygenase 
(COX)-2 inhibitors (8, 9). COX-2 inhibition may result in a tumor cell-specific 
sensitization towards radiotherapy (10) and reduction of tumor neovascularization 
(11). Expression of COX-2 correlates with shorter survival times in patients with 
glioma (12). Though selective inhibition of COX-2 is regarded superior to non-
selective COX inhibition, e.g. mediated by non-steroidal anti-inflammatory drugs 
(NSAID)s, in tumor therapy due to lacking adverse effects on gastrointestinal and 
platelet function, two available COX-2-selective inhibitors, rofecoxib and celecoxib, 
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were in discussion for lethal cardiovascular complications before this trial was 
initiated.  
The University of Tübingen Medical Center (UKT)-05 phase II trial exploited the anti-
angiogenic and radiosensitizing effects of the NSAID indomethacin (INDO) 
administered as a continuous maintenance therapy and the cytotoxic effects of an 
intensified concomitant and adjuvant (one week on/one week off) TMZ regimen in 
addition to radiotherapy in the first-line treatment of glioblastoma. 
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PATIENTS AND METHODS 
Patients 
This prospective phase II trial accrued between February 1, 2005 and October 31, 
2006. The ethics committee at the University of Tübingen (Tübingen, Germany) 
approved the trial (253/2004). UKT-05 enrolled patients at the three German 
University Medical Centers of Tübingen (n = 27), Mainz (n = 13) and Bonn (n = 1). All 
patients gave written informed consent. The main inclusion criteria comprised 
histological diagnosis of supratentorial glioblastoma, age > 18 and ≤ 65 years, 
Karnofsky performance status (KPS) of 60 or higher, no prior systemic 
chemotherapy or radiation therapy of the brain, no history of gastrointestinal 
ulceration, no anticoagulants, no orally treated diabetes mellitus, no HIV infection, 
and adequate bone marrow reserve, liver function, or renal function. 
 
Treatment and surveillance 
TMZ was administered orally before and after radiotherapy in a weekly alternating 
schedule starting at 150 mg/m2 on days 1 through 7 of 14-day cycles. Pre-irradiation 
TMZ differing from previous glioblastoma treatment schemes was intended to make 
therapeutic use of this otherwise treatment-free time interval. Radiotherapy was not 
postponed due to the administration of prior TMZ. If the beginning of radiotherapy 
coincided with days 1 through 7 of any cycle (week on TMZ), the entire cycle was 
completed first before low-dose TMZ at 50 mg/m2 was initiated. If the beginning of 
the radiotherapy coincided with days 8 through 14 (week off from TMZ), concomitant 
low-dose TMZ at 50 mg/m2 was started only after completion of the current week off 
from TMZ. According to a previously published trial (13), the dose of concomitant 
TMZ was chosen lower (50 mg/m2) than the standard set by the EORTC/NCIC trial 
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26981-22981/CE.3 (75 mg/m2) (1) in order to minimize the risk of adverse side 
effects on a combined treatment with TMZ, INDO and corticosteroids that are 
frequently required during radiotherapy. Four weeks after radiotherapy, the weekly 
alternating TMZ regimen was continued, starting at 150 mg/m2. No maximum 
number of cycles was defined. Dose adjustments of adjuvant TMZ were done 
according to weekly hemograms after every second cycle (Table 1). Treatment was 
halted for at least two weeks at a neutrophil nadir below 1.0 x 109/L and a platelet 
nadir below 50 x 109/L or a neutrophil nadir below 0.75 x 109/L or a platelet nadir 
below 30 x 109/L. With stabilization of the neutrophil nadir > 1.5 x 109/L and the 
platelet nadir > 100 x 109/L for two weeks, dose-dense TMZ treatment was resumed 
at 50 mg/m2. A treatment pause according to these guidelines was tolerated with 
clinical and MRI-documented stable disease. Adjuvant treatment with TMZ was 
discontinued at platelets below 10 x 109/L, neutrophils below 0.5 x 109/L or 
lymphocytes below 0.2 x 109/L. INDO was orally administered at 25 mg bid without 
individual dose adjustments. Adverse reactions towards INDO led to continuation of 
the trial without INDO. Standard radiotherapy was delivered in daily single fractions 
of 1.8 to 2 Gy at 5 days per week. During radiotherapy and at any lymphopenia 
grade 3 or higher, a Pneumocystis carinii pneumonia prophylaxis was administered. 
Second-line therapy was at the discretion of the treating physician. 
Toxicity monitoring was performed monthly according to the Common Terminology 
Criteria for Adverse Events (CTCAE; version 3.0). Hematologic toxicity was 
evaluated by weekly hemograms and monthly differential hemograms. Patients were 
to undergo contrast-enhanced MRI within 72 h after neurosurgery, four weeks after 
completion of radiotherapy, and every three months thereafter. Tumor progression 
was defined according to Macdonald criteria (14). 
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End points and statistical analysis 
The primary end point was median progression-free survival (PFS). Secondary end 
points were PFS rate at six months (PFS-6), overall survival (OS), OS rate at two 
years, and tumor remission rates. Assessment on an intention-to-treat basis required 
initiation of trial treatment. Survival data were calculated according to the Kaplan-
Meier method (15) starting with the day of surgery. Further comparisons were 
evaluated using the log-rank test, Fisher and Wilcoxon rank sum and the Cox 
Proportional Hazard model. In a sample size of 40 intention-to-treat subjects, the 
target was to obtain a median PFS of 10.4 months. The median PFS of 10.4 months 
was chosen because a 50% increase in PFS compared to the median PFS of 6.9 
months obtained in the experimental treatment arm of the EORTC/NCIC trial 26981-
22981/CE.3 (1) was regarded clinically relevant. The 95% confidence interval (CI) for 
the median was calculated using the exact binomial method. For acceptable toxicity, 
no more than 10% of patients should have experienced CTCAE grade 4 or 5 non-
hematologic toxicity. Early stopping rules were implemented and toxicity data were 
screened regularly. The trial would have been closed prematurely if in five of the first 
ten included patients therapy had to be discontinued within six months due to tumor 
progression, toxicity or any other reason, or if 8 of the first 20 included patients 
experienced progressive disease within ten months. Data presented here are based 
on the censoring of March 1, 2008. Risk factor assessment was done by comparing 
the prognosis of included patients with the survival predictions of a recently 
published model based on EORTC/NCIC 26981-22981/CE.3 trial data (16). Allowing 
a historical comparison with the survival data obtained in the EORTC/NCIC trial 
26981-22981/CE.3 (Table 4) (1, 16), individual survival data in UKT-05 were 
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corrected for the time interval between the day of surgery and the day of trial 
inclusion (median interval: 11 days). Treatment hazard ratios in this comparative 
analysis were computed without and with adjustment for the confounding effect of 
extent of surgery, age, performance status, and administration of corticosteroids at 
baseline which had been identified as major prognostic factors in the EORTC/NCIC 
trial 26981-22981/CE.3 (1, 16). 
 
MGMT analysis 
A tumor cell content of at least 80% was histologically determined. From each 
sample and the reference samples 200 to 500 ng of genomic DNA were treated with 
sodium bisulfite using the Qiagen EpiTect kit (Qiagen, Hilden, Germany) with the 
provided FFPE tissue protocol. The primer sequences used to detect methylated 
MGMT promoter sequences were 5′-tttcgacgttcgtaggttttcgc-3′ and 5′-
gcactcttccgaaaacgaaacg-3′. This primer combination amplifies an 81-base pair (bp) 
fragment from methylated DNA. The primer sequences used to detect unmethylated 
MGMT promoter sequences were 5′-aactccacactcttccaaaaacaaaaca-3′ and 5′-
tttgtgttttgatgtttgtaggtttttgt-3′. This primer combination amplifies a 93-bp fragment from 
unmethylated DNA (17). The PCR products were separated on 2.5% agarose gels. 
As a positive control for methylation, we used genomic DNA from the glioma cell line 
U87 with known MGMT hypermethylation. CpGenome universal unmethylated DNA 
Vial A (Chemicon International, Temecula, CA) served as a negative control for 
methylation. In addition, a control reaction without any template DNA was performed 
for both PCR experiments. 




Of 49 patients with newly diagnosed glioblastoma screened, seven patients were 
enrolled into a competing phase I/IIa trial of cilengitide, TMZ and radiotherapy (18) 
and one patient was excluded from the trial assessment retrospectively because he 
died from a Legionellae pneumonia before the trial therapy was started. Along with 
the remaining 41 patients (Table 2), one more patient than originally planned was 
accrued because at the end of the accrual period, two eligible patients consented at 
the same time. 
 
Treatment 
At the cutoff date (March 1, 2008), the median follow-up interval for PFS was 18.7 
months (95% CI, 17.8 to 34.8 months). A total of 443 cycles of intensified TMZ 
therapy were administered before and after radiotherapy. The median interval 
between surgery and the start of trial treatment was 18 days (range, 10 to 59). 
Twenty-six of 41 patients (63.4%) received a median of one treatment week TMZ 
prior to radiotherapy (range, 0 to 2). The median number of overall cycles per patient 
was 6.5 (range, 0 to 68). Thirty-nine of 41 patients (95.1%) received at least one 
cycle of TMZ during the course of their treatment. The median total dose of TMZ 
administered per patient during the entire course of the trial therapy was censored at 
17.04 g (range, 1.40 to 81.31 g). The trial treatment had to be discontinued due to 
grade 4 hematologic toxicity in 3 of 41 patients (7.3%) and due to grade 4 non-
hematologic toxicity in 1 of 41 patients (2.4%). In five of 41 patients (12.2%), the 
general health condition did not allow continuing chemotherapy. Thirty-six of 41 
patients (87.8%) completed concomitant TMZ without interruption. Twenty-eight of 
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41 patients (68.3%) received INDO either until tumor progression or censoring. The 
reasons for premature discontinuation of INDO were as follows: thrombocytopenia (n 
= 3), neutropenia (n = 1), drug-induced hepatitis (n = 1), postoperative hygroma (n = 
1), bleeding into the tumor during radiotherapy (n = 1), clinically asymptomatic 
elevation of liver enzymes (n = 1), gastric pain (n = 1), or other (n = 4). Radiotherapy 
was interrupted in three of 41 patients (7.3%) due to bleeding into the tumor during 
radiotherapy (n = 1), seizure (n = 1), and febrile gastroenteritis with ileus, septic 
disease and acute renal failure (n = 1). 
 
Toxicity 
Grade 4 hematologic toxicity per cycles was observed during adjuvant, not 
concomitant, therapy with TMZ and reported as follows: leukopenia 0.5%, 
thrombocytopenia 1.4%, neutropenia 1.4%, and lymphopenia 10.3%. Acute 
treatment-related toxicity per patient is summarized in Table 3. One grade 3 and one 
grade 5 opportunistic infection in a patient who had already been diagnosed with 
multifocal progressive disease were reported. This patient died from respiratory 
failure due to Pneumocystis carinii and cytomegalovirus lung infections ten days 
after completion of the preceding treatment week with TMZ. Overall, 17 of 41 
patients (41.5%) experienced hematologic (15 of 41, 36.6%) or non-hematologic (2 
of 41, 4.9%) grade 4/5 toxicity. 
 
Therapeutic efficacy 
Forty-one patients were assessable for outcome. Of 22 patients with measurable 
residual tumor, two patients had a partial remission. The median PFS was 7.6 
months (range, 1.4 to 34.8+ months; 95% CI, 6.2 to 10.4 months; Figure A). At the 
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censoring date, five patients (12.2%) were stable, and two of these (4.9%) were still 
on trial therapy. One patient was stable after more than 34 months on trial treatment. 
PFS-6 was 70.7% (95% CI, 54.3 to 82.2%). The one year PFS rate was 31.7% (95% 
CI, 18.3 to 46.0%). Thirty-six of 41 patients (87.8%) experienced tumor progression 
as documented by magnetic resonance imaging (MRI) or computed tomography 
(CT) scan. Twenty-five of the progressive patients were assessable for salvage 
therapy regimens, including a second resection plus nitrosourea-based 
chemotherapy in seven patients. Three patients had surgery and one patient had 
radiation therapy without adjuvant treatment. Most of the non-reoperated patients 
were also exposed to nitrosourea-based therapy (n = 11), three combined with 
reirradiation, TMZ rechallenge (n = 2) or enzastaurin (n = 1). Upon further tumor 
progression, 12 patients received third-line salvage therapy including reresection (n 
= 3), one combined with TMZ, reirradiation (n = 4), and chemotherapy with imatinib 
(n = 3) or lomustine (n = 2), either alone (n = 1) or combined with bevacizumab (n = 
1). One patient experienced two reresections, reirradiation and four anti-neoplastic 
salvage therapies. OS from the diagnosis of glioblastoma is depicted in Figure B. 
Fourteen patients were alive at the end of the trial assessment. The median OS was 
15.9 months (range, 3.3 to 34.8+ months; 95% CI, 15.0 to 23.8 months). The one 
year OS rate was 73.2% (95% CI, 56.8 to 84.2%). The administration of pre-
irradiation TMZ had no significant impact on PFS (p = 0.6212, log-rank test) or on 
OS (p = 0.2080). 
 
MGMT methylation status and survival 
Tumor specimens of 39 patients (95.1%) were assessable for MGMT promoter 
methylation analysis. Twenty-three of 39 tumors (59.0%) were diagnosed with an 
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unmethylated MGMT promoter, and 16 tumors (41.0%) displayed methylation of the 
MGMT promoter. PFS was significantly longer in patients with a methylated MGMT 
promoter (p = 0.0002*) whereas OS did not differ significantly between the two 
subgroups of patients (p = 0.1008). Moreover, the comparison with the 
EORTC/NCIC trial 26981-22981/CE.3 (1) indicated a trend in favor of UKT-05 for 
patients with methylated MGMT gene promoter with regard to median PFS (adjusted 
HR = 0.65) but not to median OS (adjusted HR = 0.91) (Table 4). Of note, these 
patients were not selected for favorable prognostic factors in comparison with the 
respective treatment arm of the EORTC/NCIC trial 26981-22981/CE.3. However, in 
patients with unmethylated MGMT gene promoter, no favorable trend was observed 
for median PFS or OS. At the cutoff date, 16 of 23 patients (69.6%) without MGMT 
promoter methylation vs. 10 of 16 patients (62.5%) with MGMT promoter methylation 
had died. The one year survival rate was 65.2% (95% CI, 42.4 to 80.8%) in patients 
without MGMT promoter methylation and 87.5% (95% CI, 58.6 to 96.7%) in patients 
with a methylated MGMT promoter. 
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DISCUSSION 
First-line therapy with intensified TMZ combined with maintained daily INDO and 
involved-field radiotherapy plus concomitant daily low-dose TMZ was shown to be 
feasible and effective in patients with glioblastoma. In line with previous studies 
following other approaches (3, 18, 19), MGMT gene promoter methylation was highly 
predictive for survival in glioblastoma patients receiving alkylating chemotherapy. 
The PFS-6 of 70.7% in UKT-05 compares well with the results of the combined 
RT/TMZ treatment arm in the phase III randomized EORTC/NCIC trial that currently 
sets the benchmark for first-line therapy of glioblastoma (PFS-6: 53.9%) (1). 
However, the median PFS of 7.6 months obtained in the UKT-05 trial is not 
relevantly superior to the historical control data of 6.9 months. To exclude the 
possibility that data were biased in the UKT-05 patient sample by selection for 
favorable prognostic factors, we compared the baseline patient characteristics in 
UKT-05 with the EORTC/NCIC trial (1, 20). This comparison revealed no significant 
imbalance between the two trials. 
As unlimited dose escalations of adjuvant TMZ were allowed in the UKT-05 trial 
protocol, the grade 4 lymphotoxicity rate per cycle was higher (10.3%) than observed 
in the recurrent glioma trial conducted at the same institutions (0.7%) (6). Notably, 
grade 3/4 lymphopenia per patient did not exceed markedly grade 3/4 lymphopenia 
reported with a phase II trial that investigated the combined concomitant and 
adjuvant therapy with the integrin inhibitor cilengitide and six courses of 
conventionally-dosed TMZ in addition to radiotherapy in patients with newly 
diagnosed glioblastoma (55.8%) (18). Moreover, the incidence of grade 3 through 5 
opportunistic infections in the UKT-05 trial (4.9%) is the lowest for all reported trials 
that tested intensified TMZ dosing schedules. 
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The most important observation of the UKT-05 trial comes from the MGMT 
methylation efficacy data: In the subgroup of patients suffering from an MGMT-
inactive glioblastoma, there was a clinically relevant trend for a superior PFS. Yet, 
this trial did not indicate that this trend transformed into an overall survival benefit. 
Compared to data from the EORTC/NCIC trial (3), patients with an unmethylated 
MGMT gene promoter appeared not to benefit from intensifying the TMZ schedule. 
This profoundly affects the concept of enhanced MGMT depletion, as current efforts 
strive for an efficient reduction of MGMT activity in the tumor tissue to overcome 
chemoresistance by applying intensified TMZ dosing regimens. Several studies 
using TMZ at a three weeks on/one week off (21 of 28 days) schedule at recurrence 
in malignant glioma (21, 22) or at a one week on/one week off schedule in non-
resectable glioblastoma (23) have investigated alternative dosing schedules for TMZ. 
Encouraging data on the beneficial effects of a first-line treatment with dose-
intensified one week on/one week off TMZ were first obtained in the experimental 
arm of a randomized phase II trial (median PFS: 10.8 months; PFS-6: 67.1%; one 
year survival rate: 56.1%). However, that trial did not provide differential survival data 
regarding the methylation status of the MGMT gene promoter (24). Preliminary 
evidence indicates that the one week on/one week off TMZ schedule could also be 
active in patients with tumors lacking MGMT gene promoter methylation (6). The 
PFS-6 of 65.2% suggests that, in the first-line treatment situation, patients with 
MGMT-expressing tumors might benefit from the intensified TMZ schedule. In 
contrast, this translates not into a relevant overall improvement regarding median 
PFS and OS, similar to other trials for patients with MGMT-active glioblastoma (1, 3, 
18, 19). Conversely, the comparative statistical analysis with the current standard 
therapy documented a possible effect on PFS but failed to show an effect on OS in 
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patients with a methylated MGMT gene promoter (Table 4) that needs to be 
assessed in randomized trials. In this regard, UKT-05 is the first trial to deliver data 
concerning the efficacy of first-line treatment with dose-intensified TMZ respecting 
the patient’s MGMT methylation status before large-scale results from the currently 
open two-armed phase III trial jointly conducted by the RTOG and the EORTC 
(RTOG trial 0525 and EORTC trial 26052-22053) comparing chemoradiotherapy with 
conventional adjuvant and dose-intensive three weeks on/one week off TMZ. 
Meanwhile, the UKT-05 experience points towards the necessity of assessing the 
MGMT methylation status prospectively and suggests treating patients with a 
methylated MGMT gene promoter according to a dose-dense TMZ protocol. 
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FIGURE LEGEND 
Fig. 1. (A) Progression-free and (B) overall survival in the 41 patients of UKT-05. 
Abbreviations: PFS-6 = progression-free survival rate at six months; MST = median 
survival time. 




























































Median PFS: 7.6 months
PFS-6: 70.7%
MST: 15.9 months
